BusinessGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02By Nasdaq OMXApr 25, 2017, 12:02 PM UTC
BusinessGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017By Nasdaq OMXApr 18, 2017, 12:01 PM UTC
BusinessGalectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017By Nasdaq OMXApr 18, 2017, 12:01 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
BusinessMadrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196By Nasdaq OMXApr 3, 2017, 11:30 AM UTC
BusinessGalectin Therapeutics Reports 2016 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 28, 2017, 12:31 PM UTC
